BCAX Company Profile and Key Details

Our AI price prediction model suggests that Bicara Therapeutics Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.33%, with price expected at $13.17 by February 26, 2026, within a range of $12.50 to $13.84 3-Month Outlook: Projected fall of -31.22%, reaching $9.67 by May 12, 2026, with a range of $8.79 to $10.52. 1-Year Outlook: Projected gain of 140.9%, with price at $33.87 by February 12, 2027, within a range of $33.61 to $35.25.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) shares are flat -0.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Bicara Therapeutics Inc. Common Stock trading at a premium to the broader market with a P/E of -6.44. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $30.63, suggesting 117.85% upside. Our AI forecast model points to short-term weakness (-6.33% over two weeks), a medium-term fall (-31.22% over three months), and a longer-term gain (140.9% over one year), with expected trading ranges indicating moderate volatility.

Bicara Therapeutics Inc. Common Stock (NASDAQ:BCAX) closed at $14.06 USD, losing -$0.74 (-5.00%) from the previous close of $14.80. The stock is currently mid-range between its 52-week high and low $7.80 and $19.71. With a market capitalization of about $770.23 million, Bicara Therapeutics Inc. Common Stock is classified as a small-cap and shows lower-than-market volatility (beta ~-0.78). Key stats such as the average daily volume over the past year has been around 549.59 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Bicara Therapeutics Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Claire Mazumdar Clemon, the company employs approximately 55 people and listed since September 13, 2024. Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors.

Wall Street analysts project EPS growth of 8.12% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 3 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $44.00 to $8.00. The high target offers 212.94% upside. The low target suggests -43.1% downside. The mean target is $26.36. This offers 87.48% upside. Bicara Therapeutics Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 21.06%. The prior quarter beat by -7.41%. Over the last six quarters, Apple has recorded several small beats. These include 247.83% in November 12, 2024.

Bicara Therapeutics Inc. Common Stock trades at a P/E ratio of -6.44, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.94 suggesting the stock is closer to book value. The P/FCF stands at -6.95, also below market averages.